

.Supplementary Information for:

**Alginate di-aldehyde modified metal-organic framework nanocarriers as delivery
and adjuvant in inactivated pseudorabies vaccination**

Wenzhu Yin,^{a,b,c} Zeyu Xu,^b Chen Chang,^a Yanhong Zhao,^a Haiyan Wang,^a Jinqiu Zhang,^a Fang Ma,^a Xiaoxin

Zuo,^a Bo Tang^{*a,b} and Yu Lu^{*a,c}

Address:

^aInstitute of Veterinary Immunology & Engineering, National Research Center of Engineering and Technology for Veterinary Biologicals, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China.

^bCollege of Veterinary Medicine, Nanjing Agricultural University, Nanjing 210095, China.

^cGuoTai (Taizhou) Center of Technology Innovation for Veterinary Biologicals, Taizhou 225300, China.

Table S1. List of primers of gI/gE gene of PRV used in this study.

| Primer | Sequence |
|--------|--|
| gI/gE | F:GGTGTTCATAATTTGTGGGTGG-3' R:GAAAGGGCCGCATGGTCTCA-3' |

Table S2. The body weight changes of mice in different groups between 1 dpi and 28 dpi.

| | Group | | | | | | |
|---------------|------------|------------|------------|------------|-------------|------------|-----------------|
| | PBS | PRV | ISA201/PRV | Alum/PRV | ZIF-7/8/PRV | ADA/PRV | ZIF-7/8-ADA/PRV |
| 1 dpi | 23.19±0.97 | 23.56±0.98 | 23.13±1.30 | 22.89±1.58 | 22.81±0.83 | 23.03±1.21 | 22.98±1.05 |
| 7 dpi | 25.31±1.37 | 25.43±1.31 | 25.09±0.65 | 25.19±0.77 | 24.92±0.63 | 25.21±0.74 | 25.45±1.11 |
| 14 dpi | 26.29±0.85 | 26.49±1.15 | 26.63±1.00 | 26.75±0.84 | 27.00±0.63 | 26.89±0.82 | 27.30±0.64 |
| 21 dpi | 28.10±0.88 | 27.10±0.78 | 28.38±0.94 | 27.77±0.84 | 28.53±0.93 | 28.27±1.15 | 28.43±1.32 |
| 28 dpi | 29.05±2.10 | 28.40±1.86 | 28.74±1.00 | 29.14±0.98 | 29.22±1.14 | 29.24±1.61 | 29.22±1.89 |

Table S3. Blood routine examination of mice in different immune groups in 7 dpi.

| | PBS | PRV | ISA201/PRV | Alum/PRV | ZIF-7/8/PRV | ADA/PRV | ZIF-7/8-ADA/PRV | Standard Range |
|--------------------|------|------|------------|----------|-------------|---------|-----------------|----------------|
| Leukocyte | 8.2 | 8.69 | 7.59 | 7.54 | 6.63 | 7.21 | 7.57 | 0.8-10.6 |
| Lymphocyte | 1.23 | 1.42 | 2.16 | 1.59 | 1.85 | 1.19 | 2.05 | 0.23-3.6 |
| Neutrophils | 0.06 | 4.48 | 1.5 | 2.46 | 6.32 | 5.52 | 4.1 | 0.6-8.9 |
| Monocytes | 0.05 | 0.08 | 0.05 | 0.09 | 0.04 | 0.07 | 0.05 | 0.04-0.14 |
| Oxyphil | 0.07 | 0.19 | 0.04 | 0.07 | 0.21 | 0.14 | 0.06 | 0.00-0.51 |
| Basophile | 0.05 | 0.02 | 0.04 | 0.01 | 0.02 | 0.04 | 0.07 | 0.00-0.12 |
| Erythrocyte | 8.05 | 8.46 | 7.07 | 8.26 | 7.58 | 7.58 | 7.58 | 6.5-11.5 |
| Platelet | 689 | 834 | 1439 | 857 | 735 | 924 | 984 | 400-1600 |

Table S4. Blood routine examination of mice in different immune groups in 14 dpi.

| | PBS | PRV | ISA201/PRV | Alum/PRV | ZIF-7/8/PRV | ADA/PRV | ZIF-7/8-ADA/PRV | Standard Range |
|--------------------|------|------|------------|----------|-------------|---------|-----------------|----------------|
| Leukocyte | 8.2 | 8.69 | 7.59 | 7.54 | 6.63 | 7.21 | 7.57 | 0.8-10.6 |
| Lymphocyte | 1.23 | 1.42 | 2.16 | 1.59 | 1.85 | 1.19 | 2.05 | 0.23-3.6 |
| Neutrophils | 0.06 | 4.48 | 1.5 | 2.46 | 6.32 | 5.52 | 4.1 | 0.6-8.9 |
| Monocytes | 0.05 | 0.08 | 0.05 | 0.09 | 0.04 | 0.07 | 0.05 | 0.04-0.14 |
| Oxyphil | 0.07 | 0.19 | 0.04 | 0.07 | 0.21 | 0.14 | 0.06 | 0.00-0.51 |
| Basophile | 0.05 | 0.02 | 0.04 | 0.01 | 0.02 | 0.04 | 0.07 | 0.00-0.12 |
| Erythrocyte | 8.05 | 8.46 | 7.07 | 8.26 | 7.58 | 7.58 | 7.58 | 6.5-11.5 |
| Platelet | 689 | 834 | 1439 | 857 | 735 | 924 | 984 | 400-1600 |

Figure S1. ^1H NMR spectrum of ADA.




Figure S2. TEM images of (A) ZIF-7/8 and (B) ZIF-7/8-ADA.




Figure S3. (A) XPS spectrum of ZIF-7/8 and high-resolution (B) C1s, (C) N1s, and (D) O1s XPS spectrum of ZIF-7/8-ADA.




Figure S4. Nitrogen adsorption-desorption isotherms of ZIF-7/8. (A) BET surface area and (B) BJH pore width.




Figure S5. TEM images of (A) PRV, (B) ZIF-7/8/PRV and (C) ZIF-7/8-ADA/PRV.




Figure S6. Adsorption of the inactivated PRV antigen by ZIF-7/8-ADA. (A) PRV cumulative adsorption curves of the ZIF-7/8-ADA in PBS solution with different volume ratios; (B) SDS-PAGE image of ZIF-7/8-ADA adsorbed PRV.




Figure S7. H&E staining images of major organs in ICR mice injected with different concentration of ZIF-7/8-ADA after 28 dpi. (A) 200 $\mu\text{g}/\text{mL}$ and (B) 1000 $\mu\text{g}/\text{mL}$. Scale bars correspond to 50 μm .




Figure S8. Cell uptake of ZIF-7/8-ADA by BMDCs. (A) The CLSM images of BMDCs, incubated with OVA-FITC, ZIF-7/8-ADA-RhB/OVA-FITC and ZIF-7/8-ADA-RhB for 12 h, respectively. Scale bar: 20 μm . The mean green (B) and red (C) fluorescence intensity of OVA-FITC and ZIF-7/8-ADA-RhB/OVA-FITC and ZIF-7/8-ADA-RhB, respectively. (D) The co-localization analyst in ZIF-7/8-ADA-RhB/OVA-FITC between ZIF-7/8-ADA-RhB and OVA-FITC.




Figure S9. H&E staining images of major organs of surviving mice after PRV-challenged with 100LD₅₀/mL dose. Scale bars represent 50 μm.




Figure S10. Flow cytometry analysis of CD11c⁺CD80⁺, CD11c⁺CD86⁺, CD11c⁺MHC-I⁺ and CD11c⁺MHC-II⁺ in BMDCs after immunized with PBS, PRV, Alum/PRV, ISA201/PRV, ZIF-7/8/PRV, ADA/PRV, and ZIF-7/8-ADA/PRV.

